RecruitingNCT06953206
Prospective, Long-term Evaluation of the SAPIEN 3 Ultra RESILIA Valve
SAPIEN Ultra RESILIA Durability EU Registry - The RESOUND-EU Registry
Sponsor
Institut für Pharmakologie und Präventive Medizin
Enrollment
500 participants
Start Date
Sep 15, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Evaluation of clinical outcomes and valve performance of the SAPIEN 3 Ultra Resilia (S3UR) valve over 10 years.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a procedure called Transcatheter aortic valve (S3UR) replacement (TAVR) for people with aortic insufficiency, aortic stenosis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDURETranscatheter aortic valve (S3UR) replacement (TAVR)
Elective transfemoral TAVi procedure with S3UR valve.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06953206
Related Trials
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
NCT052833561 location
A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm
NCT0699151720 locations
The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study
NCT04204915110 locations
Multicenter Study for the Validation of Willem AI: Aortic StenoSis Early Diagnosis With AI-electrocardiogram Study
NCT074799922 locations
Avr Thrombosis OutcoMe Study
NCT042348411 location